{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2Ffdea1866-e5d6-48ba-ae46-011ada1ab57b","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/fdea1866-e5d6-48ba-ae46-011ada1ab57b\"></iframe>","title":"Understanding the Risk of Recurrence and Related Management for Patients with Localized HER2-Positive Breast Cancer","description":"\n        <p>Dr Adam M Brufsky from UPMC Hillman Cancer Center in Pittsburgh summarizes the history of and modern advances in treating localized HER2-positive breast cancers, including strategies for monitoring and managing treatment-related toxicities.</p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/OncologyTodayLocHER2PosBC24\" rel=\"nofollow\">here</a>. </p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/8817df4f-8512-4d40-b281-b3ba06922fab/cover.jpg"}